WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Results from a clinical study conducted with patients who were diagnosed with advanced, refractory cutaneous T-cell lymphoma (CTCL) showed nearly a third of patients responded to treatment with ZOLINZA™ (vorinostat), as measured by objective response rate, according to data published in this week’s Journal of Clinical Oncology. ZOLINZA, Merck’s most recent anticancer treatment, is approved for the treatment of cutaneous manifestations in patients with CTCL who have progressive, persistent or recurrent disease on or following two systemic therapies. CTCL is a cancer of the T-cells, a type of white blood cell, which affects the skin and is a form of non-Hodgkin’s lymphoma.
